Current therapies used in the treatment of inflammatory bowel disease (IBD) are not effective in all patients. Biologic agents result in approximately 40% remission rates at 1 year in selected populations, prompting a growing interest in combining biologic therapy to improve outcomes. There are limited published data regarding the efficacy and safety of combination targeted therapy in IBD specifically, which include only 1 exploratory randomized control trial and 3 case reports or series. This review evaluates the published literature regarding this therapeutic paradigm in IBD and its extensive utilization in the treatment of other immune-mediated inflammatory disorders. The combination of biologic therapies demonstrates variable degrees of efficacy and highlights some safety concerns, depending upon the agents used and the disease state treated. A trial (Clinical Trials.gov Identifier: NCT02764762) combining vedolizumab and adalimumab is currently underway evaluating the effectiveness and safety of this approach in patients with Crohn's disease, which should provide further insight into this treatment concept. While combination biologic therapy is an attractive strategy, the lack of consistent superior efficacy as well as safety concerns militates the need for further trials prior to its general application in IBD.
T he therapeutic goal in inflammatory bowel disease (IBD) has shifted during recent years from control of symptoms toward achieving clinical remission and endoscopic healing to prevent disease progression, namely bowel damage and disability. 1 This was stimulated by the development of biologic agents directed at specific components of the immune system and inflammatory cascade. 2 However, despite the development of these targeted therapies the most effective biologic agents only achieve approximately 40% clinical remission rates in responders after 1 year on therapy, highlighting a persistent therapeutic gap. [3] [4] [5] Given the extensive redundancy of the inflammatory network, an intuitive approach to improving treatment outcomes involves the combination of available targeted therapies.
Most of the experience in Crohn's disease (CD) and ulcerative colitis (UC) has relied on the combination of targeted biologics with immunomodulators, which is more effective than biologics alone. 4 We have systematically compiled the available published experience in combining biologics in these diseases and reviewed, in parallel, the data accumulated in the treatment of other immune-mediated inflammatory disorders, because this could inform gastroenterologists about efficacy and safety concerns with such combinations (Figure 1 ).
Combination Therapy in Inflammatory Bowel Disease
The data on the use of combination targeted therapy in IBD are limited to 4 publications ( Table 1) . [6] [7] [8] [9] An exploratory multicenter, double-blind, placebocontrolled trial evaluated the safety and tolerability of combining infliximab, an anti-tumor necrosis factor (TNF)-a agent, with natalizumab, a humanized IgG 4 monoclonal antibody that targets the a4 integrin in the treatment of CD. Patients had active disease while on infliximab (defined as Crohn's Disease Activity Index !150) and received either natalizumab or placebo every 4 weeks for an 8-week period, with safety assessed through Week 10. The authors found no difference in treatment-emergent adverse events (AEs) or infectious outcomes between the combination and placebo groups, which were reported in 92% and 100% and 27% and 30% of each group, respectively. Although not powered to assess efficacy, there was no difference a Authors share co-senior authorship.
in improvement of CD symptoms found between the groups (P ¼ .08). 6 An additional 2 cases were reported describing the combination of an anti-TNF agent and vedolizumab, a gut-specific monoclonal antibody that targets the a4b7 integrin, in controlling both luminal and extraintestinal manifestations of CD. In 1 case, the combination of infliximab and vedolizumab overlapped in a patient with active luminal CD resulting in symptomatic improvement; however, with discontinuation of infliximab, erythema nodosum developed that only improved with its reintroduction. Subsequent vedolizumab withdrawal worsened the CD-related symptoms, highlighting the respective luminal and extraintestinal benefits of vedolizumab and infliximab. Notably, no AEs were reported. 7 In a similar case, a patient with a history of UC with a J-pouch complicated by anti-TNF refractory pouchitis improved with the addition of vedolizumab. With the initiation of vedolizumab, the patient's spondylarthritis worsened requiring the addition of the anti-TNF etanercept. As with the previous case, the anti-TNF improved the extraintestinal manifestations without AEs noted at 10 months of follow-up. 8 Additionally, a case series of 3 patients, 2 with CD and 1 with UC, who were in remission on anti-TNF therapy, were subsequently treated with ustekinumab, a monoclonal antibody targeting the p40 subunit shared by interleukin-12 and interleukin-23, for anti-TNF-induced psoriasis. Although the psoriasis was not improved, no AEs were reported after a median follow-up of 21 months. 9 The favorable safety outcomes reported when combining natalizumab and infliximab in the treatment of refractory CD, the safety exhibited in the 2 case reports combining anti-integrin therapy and anti-TNF agents, and the gut-specific immunosuppressive effects of vedolizumab each makes the combination of these therapeutic classes an attractive option. To further determine the safety and efficacy of combining biologic agents in the treatment of IBD, a phase 4, open label study evaluating the use of vedolizumab in combination with adalimumab and methotrexate (MTX) (EXPLORER study) has started enrolling 60 patients with moderateto-severe active CD diagnosed within 24 months of inclusion. Patients must be stratified as having high-risk CD with a !20% chance of complication by Year 2. Participants will receive combination adalimumab and Trials.gov Identifier:  NCT02764762) . Notably, however, because this trial has no comparator arm, the safety and efficacy outcomes from clinical trials and postmarketing studies evaluating these individual medications will serve as the benchmark for comparison.
Combination Therapy in Dermatologic Conditions
The use of combined biologic agents has been explored for the treatment of psoriasis and its associated joint manifestations (Table 2) . Anti-TNF agents and ustekinumab have been used concomitantly to treat this condition and provide some safety data for these 2 agents commonly used in the treatment of CD. Although the evidence is limited to case reports and a small case series, these publications nevertheless raise safety concerns that require formal evaluation before using this combination in IBD.
Two of the 3 case reports using this combination demonstrated improved psoriasis and psoriatic arthritis, but noted 2 AEs. Cuchacovich et al 10 reported the successful use of etanercept with ustekinumab to treat the skin and nail manifestations and synovitis that were occurring secondary to severe refractory psoriasis and psoriatic arthritis. Improved composite disease activity indices and no AEs were noted at 11 months of follow-up on these combined agents. 10 A second patient whose disease remained active on etanercept was switched to ustekinumab monotherapy. Although this rapidly improved his psoriatic lesions, ongoing arthritis prompted the readdition of etanercept. After 5 months of therapy the patient developed unstable angina requiring cardiac stent placement. Although temporally associated with the initiation of combination therapy, it is unclear if this AE is directly related. 11 The third case failed to demonstrate improvement of psoriasis-associated joint manifestations with this therapeutic combination. Etanercept was subsequently replaced with adalimumab, 40 mg weekly, and while the patient's dermatologic manifestations remained under excellent control, her joint pain persisted. She subsequently developed furuncles and autoimmune hemolytic anemia requiring antibiotics and rituximab (RTX). Although able to resume combination therapy despite ongoing joint symptoms, this case highlights a second AE of unclear association with duel targeted therapy. 12 An observational case series of 4 patients with 16.2 patient years of combined ustekinumab and anti-TNF agent exposure for the treatment of psoriasis and psoriatic arthritis demonstrated efficacy, but raised additional infectious concerns. One patient's arthritis flare was treated with ustekinumab combined first with adalimumab and then certolizumab without complication; however, the other 3 subjects suffered AEs likely related to dual immunosuppression. A 67-year-old man treated with ustekinumab and etanercept had a satisfactory clinical response, but he developed herpes zoster outbreaks after ustekinumab injections, which necessitated etanercept dose reduction and the initiation of valacyclovir. Another patient treated with etanercept required the addition of ustekinumab to achieve disease control; however, he subsequently developed a retrotonsillar abscess requiring drainage and antibiotics.
The final patient was treated with ustekinumab and adalimumab, during which she developed 2 episodes of erysipelas of the lower extremity and bacterial pneumonia. 13 Although other biologic combinations with etanercept have been described, these have not been targeted agents used in the treatment of IBD and the rates of AEs have been variable. Efalizumab is an antiadhesion molecule that binds to and decreases expression of CD11a on leukocytes, thereby preventing interaction with intercellular adhesion molecule-1 and leukocyte trafficking into tissue.
14 Initially approved to treat psoriasis, it was removed from the market in 2009 because of an association with progressive multifocal leukoencephalopathy. Two cases have been published evaluating its combination with anti-TNF agents with 1 associated AE. The first case described a 49-year-old woman suffering from psoriasis and psoriatic arthritis whose joint symptoms were dramatically improved with etanercept. Efalizumab was added to treat recalcitrant psoriatic skin lesions, which improved at Week 6. No AEs were reported with this combination. 15 The other case published in 2009 described the development of tuberculosis with this same combination. The patient had been on etanercept for pustular psoriasis but because of active skin lesions was switched to efalizumab. This improved her skin lesions but failed to control her joint pains, thus prompting the readdition of etanercept. Although her skin and joint manifestations improved, she developed a chronic cough and was diagnosed with tuberculosis in the setting of a previously positive tuberculin skin test. 16 The history of a positive tuberculin skin test in this patient calls into question the role combination therapy played in the development of tuberculosis because anti-TNF monotherapy is associated with the reactivation of latent tuberculosis. A large case series described 20 subjects with both psoriasis and psoriatic arthritis treated with efalizumab combined with either etanercept or infliximab for a median duration of 16 months. Eighteen of the subjects were treated with efalizumab combined with etanercept at a dose of 25 mg or 50 mg weekly or 25 mg twice weekly, whereas 2 subjects received efalizumab combined first with etanercept and then infliximab. In each case efalizumab was noted to effectively treat the subjects skin while anti-TNF therapy was required for successful control of joint symptoms.
Mild AEs were noted, including 8 patients who developed upper or lower respiratory tract infections and 5 patients with dysplastic skin lesions, basal cell or squamous cell carcinoma of the skin. 17 Alefacept is a LFA-3/IgG 1 recombinant protein that binds CD2 on memory effector T lymphocytes and CD16 on accessory cells to inhibit T-cell activation. 18 Three cases were reported where it was combined with etanercept to treat psoriasis and psoriatic arthritis. In each patient, etanercept was effective for controlling the patient's psoriatic arthritis; however, because of ongoing skin lesions, alefacept was given as 12-24 weekly injections and repeated on an as-needed basis. In all 3 patients, this resulted in a significant improvement of the skin lesions for greater than 8 weeks after alefacept treatment. No AEs or infections were reported. 19 
Combination Therapy in Rheumatologic Conditions
Most of the published literature on combination biologic agents is in the treatment of rheumatologic conditions and has been performed to improve the efficacy of biologic monotherapy (Table 3) . Anti-TNF agents are highly efficacious in treating rheumatologic diseases and, as in IBD, frequently serve as a cornerstone of therapy. 20 Although combination therapy often focuses on using agents from different drug classes to enhance efficacy, Sheehy et al 21 reported the combination of 2 anti-TNF agents in the treatment of a patient suffering from HLA-B27-associated arthropathy. This 28-year-old man's disease had been refractory to 5 traditional disease-modifying antirheumatic drugs (DMARDs) and 5 biologic therapies. After an infusion of RTX failed to improve his synovitis and he developed spinal symptoms, combination therapy with 2 anti-TNF agents was offered. Infliximab, 5 mg/kg every 8 weeks, was started with etanercept, 25 mg twice weekly, with cotrimoxazole prophylaxis for Pneumocystis jirovecii pneumonia. A dramatic improvement of symptoms and erythrocyte sedimentation rate were noted and he was in remission at 6 months without observed AEs. 21 The authors believed the combination of these 2 anti-TNF agents would be worthwhile because of their slightly different modes of action. 22, 23 Furthermore, the excellent safety profile of both therapies and the subsequent reduction of the infliximab infusion dosage to 3 mg/kg every 8 weeks resulted in a total cost of combination therapy comparable with infliximab dosed at 5 mg/kg alone.
The combination of anti-TNF agents with targeted therapies having different mechanisms of action has raised additional safety concerns in the treatment of rheumatologic conditions. Abatacept inhibits T-lymphocyte activation by binding to CD80 and CD86, blocking the interaction with CD28 and the costimulatory signal needed for full lymphocyte activation. A 1-year randomized, double-blind, placebo-controlled study In another randomized controlled trial, 80 patients received etanercept, 25 mg twice a week; 81 patients received etanercept, 25 mg twice a week, with anakinra, a recombinant interleukin-1 receptor antagonist, at a dose of 100 mg daily; whereas a third group received etanercept, 25 mg weekly, combined with anakinra, 100 mg daily. 25 Patients were followed for 24 weeks with the primary outcome being the percentage of patients achieving a 50% improvement in tender or swollen joints. Although all 3 groups improved from baseline there was no difference in efficacy. Significant safety concerns were observed with 90%-95% of patients reporting an AE. The combination groups had a higher number of serious AEs (14.8% in the full-dose combination vs 2.5% in the etanercept group), a higher number of events resulting in medication withdrawal (7.4% vs 0% in full-dose combination and the etanercept group, respectively) and a higher number of injection site reactions (70.4% vs 40% in the full-dose combination and etanercept group, respectively). Infections made up 9 of the 16 serious events in those receiving combination therapy and serious infections occurred in 7.4% of the patients on full-dose combination therapy (vs 0% in the etanercept-only group). One of these patients, a 70-year-old individual with pulmonary fibrosis, passed away after developing pneumonia and pulmonary insufficiency. 26 A pilot study combined a CD4 monoclonal antibody, which results in antibody-dependent cell-mediated cytotoxicity and depletion of CD4 T-cells, with a bivalent TNF antagonist that were both produced in The Oxford Therapeutic Antibody Centre. 27 Eight patients with active RA were divided into 2 groups. Five of the patients received treatment with a single dose of the anti-TNF therapy followed by 4 daily infusions of the anti-CD4 agent. A second treatment with the anti-TNF agent was given for a disease flare with the combination repeated for a second flare. The other 3 patients received the anti-TNF agent at Weeks 0, 4, and 8 and the anti-CD4 agent weekly from Weeks 0 through 11. No infections were observed during the follow-up period, which ranged from 17 through 49 months. However, all patients in the first group and 2 of the 3 patients in the second group experienced an infusion-related reaction. Four of the patients developed a maculopapular rash during treatment as is commonly seen with anti-CD4 monoclonal antibody therapies. 28 RTX is a chimeric monoclonal antibody that results in the depletion of CD20 expressing B-cells and is approved to treat non-Hodgkin lymphoma and RA in patients who have had an inadequate response to anti-TNF agents. 29 It is used successfully in combination with MTX to improve the symptoms and physical function of patients with RA; however, to improve efficacy it has been combined with other targeted therapies, particularly anti-TNF agents. 30, 31 Two case series demonstrated the efficacy of its addition to etanercept, with only a single described infectious event. Koumakis et al 32 reported their experience with 2 patients, the first of whom was a 45-yearold woman with RA unresponsive to conventional DMARDs and adalimumab monotherapy. She subsequently received 2 cycles of RTX followed by etanercept, 50 mg per week. Although this resulted in remission after a disease flare, subsequent remission was obtained with the combination of both etanercept and cycles of RTX every 6 months. The second patient was a 32-yearold man with RA who failed to achieve remission with adalimumab prompting the initiation of RTX without therapeutic response. The addition of etanercept to cycles of RTX given every 6 months resulted in remission and no AEs were noted in these patients after 4 years and 18 months of follow-up. 32 Feuchtenberger et al 33 described 2 patients receiving the same combination with significant improvement, as determined by the DAS28 score, C-reactive protein, and radiologic assessment. The first patient was a 62-yearold woman with active RA on etanercept, prednisolone 2.5 mg, and leflunomide. RTX was added as 4 weekly infusions. Thirteen months after B-cell regeneration, the patient was diagnosed with pneumonia requiring antibiotics and had 3 subsequent acute exacerbations of her chronic bronchitis over the following 23 months. Because of increasing disease activity, retreatment with RTX was needed after 6 years, but clinical remission was achieved. Similarly, a 33-year-old woman with RA and ongoing joint symptoms on etanercept was successfully treated with 4 weekly infusions of RTX, and only experienced minor synovialitis in the left elbow joint. No radiologic progression was noted over the next 3 years and clinical remission was maintained during the 6-year follow-up period, without adverse infectious events. 33 A retrospective analysis of 18 patients with active RA who received RTX therapy after previous treatment with up to 6 DMARDs and 3 anti-TNF agents reaffirmed the safety of this combination. Each patient received 2 infusions within 2 weeks. Six of the patients who had an inadequate clinical response were started on etanercept with significant improvement of clinical and serologic parameters within 2 months. A second cycle of RTX was given with reoccurrence of disease activity. The interval between RTX infusions was 8.2 AE 1.8 months in the patients receiving only RTX and 10.2 AE 6.9 months in the group combining RTX with etanercept, which was not statistically significant. No serious infections were noted, although reactivation of perioral herpes simplex occurred in a patient on combination therapy. 34 A formal evaluation of this combination was performed in the SUNDIAL II trial where 176 patients with active RA, while on a biologic therapy, received 2 doses of RTX during this 48-week open-label study. If the subjects' disease remained active, a second course was given after Week 24. Approximately 85% of the patients were receiving an anti-TNF agent with 52.8% receiving a DMARD, such as MTX or leflunomide. Overall there was a serious AE rate of 24.3 per 100 patient years (95% confidence interval, 15.5-38.1) during the first 24 weeks of the study and no significant trend with relation to the particular biologic used (6 reported events with adalimumab, 4 with etanercept alone, and 4 with infliximab and MTX). Of the 3 serious infectious events noted in the first 24 weeks, only one was in the anti-TNF combination group and was characterized as bronchitis. Although 3 deaths occurred during the 48-week study period (cardiopulmonary arrest, ruptured aortic aneurysm, respiratory failure), none were secondary to infectious complications and overall rates of serious AEs and serious infectious events were consistent with studies where RTX was the only biologic agent. 35, 36 Greenwald et al 37 performed the TAME study, which was a randomized, double-blinded, placebo-controlled study to evaluate RTX given in combination with MTX and an anti-TNF agent. Fifty-four patients with active RA while on etanercept or adalimumab in addition to MTX, 10-25 mg/wk, were randomized to receive RTX or placebo at Day 1 and Day 15. A total of 33 patients received RTX and 18 received placebo. They were followed for 24 weeks with the primary endpoint being the proportion of patients developing at least 1 serious infection through Week 24. The proportion of AEs were 83% and 94% in the placebo and RTX groups, respectively. The number of infections per 100 patient-years was numerically higher in the placebo group than in the combination group (316.76 vs 215.50, respectively), but this was not statistically significant. There was only 1 serious infection in the combination group and none in the placebo group, which did not differ significantly. Overall, this highlighted that the safety profile of combining RTX with an anti-TNF agent and MTX is favorable, although the small sample size is a major limitation and the study was not powered to assess efficacy. 37 Multiple trials have evaluated the combination of non-anti-TNF biologic agents, of which 2 included RTX. Although most of the 176 patients in the SUNDIAL II trial were receiving anti-TNF therapy in addition to RTX, 26 subjects (14.8% of the study group) were using abatacept, of which 9 were also receiving MTX. Five of the 19 serious AEs were noted in this group during the first 24 weeks, 3 with abatacept alone. Three of these were classified as serious infectious events (2 episodes of cellulitis in 1 patient and 1 case of pneumonia). Although this study demonstrated no evidence of an increased safety signal overall, extrapolating this generalization to the abatacept subgroup is difficult because of the small sample size. 36 The AUGUST III study combined atacicept, which is a recombinant fusion protein that interferes with the activity of B-lymphocyte stimulator and APRIL (a proliferation-inducing ligand), with RTX in the treatment of RA. This phase II, randomized, doubleblind, placebo-controlled trial included a 7-week RTX treatment period (2 doses at Weeks 1 and 3), a 25-week atacicept/placebo treatment (randomized at Week 7), and a 32-week follow-up period. Twenty-seven patients were randomized, although 4 patients in the atacicept group and 5 in the placebo group were retreated with RTX in the post-treatment follow-up period resulting in an unbalanced randomization. Overall the safety signature was favorable with 295 mostly mild or moderate AEs across treatment and placebo groups (94.4% vs 100%, respectively). Although there were fewer infections in the atacicept group compared with placebo (44.4% vs 66.7%, respectively), there was no significant difference in clinical response observed between the 2 groups. 38 The ASSURE trial evaluated the safety of abatacept in combination with background nonbiologic or biologic DMARDs in patients with active RA. It consisted of a 1-year double-blind portion where patients received either placebo or abatacept (10 mg/kg). A total of 1441 patients were randomized, with 90 and 56 patients receiving anti-TNF agents in the treatment and placebo groups, respectively, and 23 patients receiving anakinra. The frequency of AEs in the subgroup receiving background biologic therapy was higher than in the placebo group (95.1% vs 89.1%), as were discontinuations because of AEs (8.7% vs 3.1%). Similarly, serious AEs were more frequent in the combination group (22.3% vs 12.5%) as were serious infections (5.8% vs 1.6%). Of significant safety concern is that 7% of patients on background biologic therapy and abatacept developed malignancies (2 basal cell carcinomas and 1 squamous cell carcinoma) compared with 2% of subjects in the placebo group. The authors noted that the small group that received anakinra and abatacept had a lower frequency of serious AEs compared with placebo (15.4% vs 20%, respectively), although serious infections occurred more frequently (7.7% vs 0%, respectively). 39 Based on the lower frequency of serious AEs in the subgroup receiving abatacept and anakinra in the ASSURE trial, Record et al 40 used these agents to treat selective patients with refractory systemic juvenile idiopathic arthritis. This retrospective study described 4 steroid-dependent patients ages 2-10 years old in whom abatacept was added to anakinra. All experienced marked clinical improvement and were able to reduce the dose of anakinra and steroids. During 8-17 months of follow-up, no infusion reactions, significant infections, or other serious AEs were noted. 40 
Other Immune-Mediated Inflammatory Disorders
The use of combination biologic agents in other autoimmune conditions is limited to 1 published case (Table 4) . Necrotizing scleritis associated with granulomatosis with polyangiitis, previously called Wegner granulomatosis, was treated with a combination of anti-TNF therapy and RTX. Because of active scleritis, this 71-year-old man received infliximab at Weeks 2, 6, and 12, starting approximately 3 weeks after receiving a cycle of RTX that was given as 2 intravenous infusions 2 weeks apart. Control of his scleritis was obtained by Week 6 allowing his systemic corticosteroids to be reduced for the following 12 months without reported AEs. This highlights the potential use of infliximab in achieving disease control while awaiting clinical benefit from RTX. 41 
Conclusions
The use of combination biologic therapy in IBD is an attractive therapeutic option, There are limited published studies on this treatment paradigm in IBD. However, the safety outcomes from other immunemediated inflammatory disorders where this has been used, particularly the randomized control trial data in rheumatology, provide a cautionary message. The findings from these studies signal a safety concern when biologics are used concurrently, especially when one agent is an anti-TNF. However, unlike other autoinflammatory conditions, IBD has the benefit of effective and safe gut-specific anti-integrin therapies that can provide a platform off of which combinations can be used. The sole randomized control trial in IBD combined infliximab with an anti-integrin agent and showed no adverse safety signal compared with monotherapy. That said, further information from larger trials is needed to document efficacy and confirm safety before the routine combination of biologic agents with anti-integrin therapy can be used.
Further studies in IBD should ideally be developed as randomized control trials to provide comparative efficacy and safety endpoints of combination therapies.
The benefits of this study design were seen in the rheumatologic literature where it provided vital outcomes data. An initial focus needs to be placed on safety, and once confirmed, followed by larger studies powered to demonstrate efficacy. Although separate evaluations of effect in CD and UC are needed, groups at high risk for progression or severe disease would likely benefit most from this early aggressive approach and would be an ideal initial study population given the potentially dire consequences of untreated severe disease.
In addition to outcomes consideration, economic cost will likely play an increasing role in the real-world application of this therapeutic strategy. Biologic agents have changed the economic landscape of IBD driving an increasing percentage of associated costs. 42 Despite improved outcomes, they have not consistently been shown to be cost-effective, particularly as maintenance agents and in certain subgroups. 43, 44 However, when evaluating the economics of combination targeted therapy one must recognize the limitations of the published literature evaluating biologics, including a lack of studies comparing the cost of different agents, variation in the adopted effectiveness measures, and the market where the cost analysis is being studied. Efficacy and safety outcomes of combination therapy with biologic agents in specific subgroups need to be determined before a cost-benefit analysis can be undertaken. However, there is a precedent for the cost effectiveness of early aggressive therapy in improving quality-adjusted life years, as seen with an early top down approach in moderate-to-severe CD. 45 Although dual biologic agents are more expensive than immunomodulator combinations, improved efficacy and the possible savings associated with of biosimilars may offset the cost, particularly in certain populations. Furthermore, short maintenance schedules have been shown to be cost effective, lending itself to short coinduction with dual biologic agents and then transitioning to monotherapy, as proposed in the EXPLORER trial. 46, 47 Increasing attention to the use of combination biologic agents and the possible incorporation of future small molecule therapies hold great promise in closing the remaining therapeutic gap that exists in IBD. Results from the current EXPLORER study evaluating this paradigm and hopefully future trials will provide the needed data to consider this approach more broadly. 
